

Global Injectable Drug Delivery Market - Trends and Forecast to 2024

<https://marketpublishers.com/r/G865946B23FEN.html>

Date: April 2017

Pages: 871

Price: US\$ 4,200.00 (Single User License)

ID: G865946B23FEN

Abstracts

Synopsis:

Global Injectable Drug Delivery Market is expected to reach USD 789.7 billion by 2024, at a CAGR 11.5% during the forecast period of 2017 to 2024. The report contains 871 pages of exclusive premium insights with 954 tables and 50 figures.

The global injectable drug delivery market has been segmented On the basis of product type into devices and formulations.

Based on application the market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

On the basis of usage patter the market is segmented into curative care, immunization, and others.

Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.

Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.

Major Players Operating in this market:

Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd. among others

Regions Covered In The Scope Of The Report:

Global (North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Turkey, Rest of Europe), Asia-Pacific (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of APAC), South America (Brazil, Rest of South America), Middle East and Africa (South Africa, Rest of MEA))

Contents

1 INTRODUCTION

- 1.1. OVERVIEW OF THE GLOBAL INJECTABLE DRUG DELIVERY MARKET
- 1.2. MARKET SEGMENTATION & COVERAGE
 - 1.2.1. CURRENCY AND PRICING
 - 1.2.2. LIMITATION
 - 1.2.3. STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1. KEY TAKEAWAYS
- 2.2. ARRIVING AT THE GLOBAL INJECTABLE DRUG DELIVERY MARKET SIZE
 - 2.2.1. MARKET CRACKDOWN APPROACH
 - 2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
 - 2.2.3. DATA TRIANGULATION
 - 2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
 - 2.2.5. KEY DATA POINTS FROM SECONDARY SOURCES
 - 2.2.6. PORTER'S FIVE FORCES MATRIX
- 2.4. GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
- 2.5. ASSUMPTIONS

3 MARKET LANDSCAPE SUMMARY

4 PREMIUM INSIGHTS

- 4.1. OVERVIEW
- 4.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
- 4.3. MARKET OVERVIEW
 - 4.3.1. DRIVERS
 - 4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
 - 4.3.1.2. INCREASING DEMAND OF SELF INJECTION DEVICES
 - 4.3.1.3. GROWTH OF BILOGICS AND BIOSIMILARS MARKET
 - 4.3.1.4. TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET
 - 4.3.2. RESTRAINTS
 - 4.3.3. OPPURTUNITIES
 - 4.3.4. THREATS
- 4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES

5 INJECTABLE DRUG DELIVERY MARKET, BY TYPE

5.1. OVERVIEW

5.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

5.2.1. INJECTABLE DRUG DELIVERY DEVICES

5.2.2. INJECTABLE DRUG DELIVERY FORMULATIONS

6 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

61. OVERVIEW

6.2. CONVENTIONAL INJECTION DEVICES

6.2.1. BY MATERIAL

6.2.1.1. GLASS

6.2.1.2. PLASTIC

6.2.2. BY PRODUCT

6.2.2.1. EMPTY SYRINGES

6.2.2.2. PREFILLED SYRINGES

6.2.3. BY USABILITY

6.2.3.1. REUSABLE SYRINGES

6.2.3.2. DISPOSABLE SYRINGES

6.3. SELF INJECTION DEVICES

6.3.1. NEEDLE FREE INJECTORS

6.3.1.1. BY PRODUCT

6.3.1.1.1. EMPTY NEEDLE FREE INJECTORS

6.3.1.2. 2. PREFILLED NEEDLE FREE INJECTORS

6.3.1.2. BY TECHNOLOGY

6.3.1.2.1. JET BASED NEEDLE FREE INJECTORS

6.3.1.2.2. SPRING BASED NEEDLE FREE INJECTORS

6.3.1.2.3. LASER POWERED NEEDLE FREE INJECTORS

6.3.1.2.4. VIBRATION BASED NEEDLE FREE INJECTORS

6.3.1.3. BY USABILITY

6.3.1.3.1. REUSABLE NEEDLE FREE INJECTORS

6.3.1.3.2. DISPOSABLE NEEDLE FREE INJECTORS

6.3.2. AUTO INJECTORS

6.3.2.1. BY PRODUCT

6.3.2.1.1. EMPTY AUTO INJECTORS

6.3.2.2. 2. PREFILLED AUTO INJECTORS

- 6.3.2.2. BY TECHNOLOGY
 - 6.3.2.2.1. AUTOMATED AUTO INJECTORS
 - 6.3.2.2.2. MANUAL AUTO INJECTORS
- 6.3.2.3. BY DESIGN
 - 6.3.2.3.1. STANDARDIZED AUTO INJECTORS
 - 6.3.2.3.2. CUSTOMIZED AUTO INJECTORS
- 6.3.2.4. BY USABILITY
 - 6.3.2.4.1. REUSABLE AUTO INJECTORS
 - 6.3.2.4.2. DISPOSABLE AUTO INJECTORS
- 6.3.3. PEN INJECTORS
 - 6.3.3.1. BY PRODUCT
 - 6.3.3.1.1. SINGLE CHAMBERED PEN INJECTORS
 - 6.3.3.2. 2. DUAL CHAMBERED PEN INJECTORS
 - 6.3.3.2. BY DESIGN
 - 6.3.3.2.1. STANDARDIZED PEN INJECTORS
 - 6.3.3.2.2. CUSTOMIZED PEN INJECTORS
 - 6.3.3.3. BY USABILITY
 - 6.3.3.3.1. REUSABLE PEN INJECTORS
 - 6.3.3.3.2. DISPOSABLE PEN INJECTORS
- 6.3.4. WEARABLE INJECTORS
- 6.3.5. OTHER INJECTABLE DEVICES

7. INJECTABLE DRUG DELIVERY FORMULATION MARKET, BY PRODUCT TYPE

- 7.1. OVERVIEW
- 7.2. CONVENTIONAL DRUG DELIVERY FORMULATIONS
 - 7.2.1. SOLUTIONS
 - 7.2.3. RECONSTITUED/LYOPHILIZED FORMULATIONS
 - 7.2.3. SUSPENSIONS
 - 7.2.3. EMULSIONS
- 7.3. NOVEL DRUG DELIVERY FORMULATIONS
 - 7.2.1. COLLOIDAL DISPERSIONS
 - 7.2.1.1. LIPOSOMES
 - 7.2.1.2. NIOSOMES
 - 7.2.1.3. POLYMERIC MIXED
 - 7.2.1.4. NANOPARTICLES
 - 7.2.1.4.1. NANOSUSPENSIONS
 - 7.2.1.4.2. NANOEMULSIONS/MICROEMULSIONS
 - 7.2.1.4.3. SOLID LIPID NANOPARTICLES

- 7.2.2. MICROPARTICLES
 - 7.2.2.1. MICROSPHERES
 - 7.2.2.2. MICROCAPSULES
- 7.2.3. LONG LASTING FORMULATIONS

8. INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

- 8.1. OVERVIEW
- 8.2. AUTOIMMUNE DISEASES
 - 8.2.1. RHEUMATOID ARTHRITIS
 - 8.2.2. MULTIPLE SCLEROSIS
 - 8.2.3. CHRON'S DISEASE
 - 8.2.4. PSORIASIS
 - 8.2.5. OTHER AUTOIMMUNE DISEASES
- 8.3. HORMONAL DISORDERS
 - 8.3.1. DIABETES
 - 8.3.2. ANEMIA
 - 8.3.3. REPRODUCTIVE HEALTH DISEASES
 - 8.3.4. ANTITHROMBOTIC/THROMBOLYTIC THERAPY
 - 8.3.5. GROWTH HORMONE DEFICIENCY (GHD)
- 8.4 ORPHAN DISEASES
- 8.5 ONCOLOGY
- 8.6 OTHERS
 - 8.6.1. PAIN MANAGEMENT
 - 8.6.2. ALLERGY TREATMENT
 - 8.6.3. AESTHETIC TREATMENT
 - 8.6.4. HEPATITIS C
 - 8.6.5. HEMOPHILIA

9. INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

- 9.1. OVERVIEW
- 9.2. CURATIVE CARE
- 9.3. IMMUNIZATIONS
- 9.4. OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)

10 INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

- 10.1. OVERVIEW
- 10.2. SKIN
- 10.3. CIRCULATORY/MUSKOSKELETAL
- 10.4. ORGANS
- 10.4. CENTRAL NERVOUS SYSTEM

11 INJECTABLE DRUG DELIVERY MARKET, BY END USERS

- 11.1. OVERVIEW
- 11.2. HOSPITALS AND CLINICS
- 11.3. HOME HEALTHCARE SETTINGS
- 11.4. RESEARCH LABORATORIES
- 11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
- 11.6. OTHERS

12 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

- 12.1. OVERVIEW
- 12.2. DIRECT TENDERS
- 12.3. HOSPITAL PHARMACY
- 12.4. PHARMACY STORES
- 12.5. ONLINE PHARMACY
- 12.6. OTHERS

13 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. COUNTRYWISE INJECTABLE DRUG DELIVERY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

- 13.1.1. NORTH AMERICA
 - 13.1.1.1. U.S.
 - 13.1.1.2. CANADA
 - 13.1.1.3. MEXICO
- 13.1.2. EUROPE
 - 13.1.2.1. GERMANY
 - 13.1.2.2. FRANCE
 - 13.1.2.3. U.K.
 - 13.1.2.4. ITALY
 - 13.1.2.5. SPAIN

- 13.1.2.6. RUSSIA
- 13.1.2.7. TURKEY
- 13.1.2.8. BELGIUM
- 13.1.2.9. NETHERLANDS
- 13.1.2.10. SWITZERLAND
- 13.1.2.11. REST OF EUROPE
- 13.1.3. ASIA-PACIFIC (APAC)
 - 13.1.3.1. JAPAN
 - 13.1.3.2. CHINA
 - 13.1.3.3. SOUTH KOREA
 - 13.1.3.4. INDIA
 - 13.1.3.5. AUSTRALIA
 - 13.1.3.6. SINGAPORE
 - 13.1.3.7. THAILAND
 - 13.1.3.8. MALAYSIA
 - 13.1.3.9. INDONESIA
 - 13.1.3.10. PHILIPPINES
 - 13.1.3.11. REST OF APAC
- 13.1.4. LATIN AMERICA
 - 13.1.4.1. BRAZIL
 - 13.1.4.2. REST OF LATIN AMERICA
- 13.1.5. MIDDLE EAST AND AFRICA
 - 13.1.5.1. SOUTH AFRICA
 - 13.1.5.2. REST OF MIDDLE EAST AND AFRICA
- 13.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

14 INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE

- 14.1. GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.2. U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.4. APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.6. MIDDLE EAST AND AFRICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
- 14.7. MERGERS & ACQUISITIONS

14.8. NEW PRODUCT DEVELOPMENT & APPROVALS

14.9. EXPANSIONS

14.10. REGULATORY CHANGES

14.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

15 INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES

15.1 BAXTER INTERNATIONAL, INC.

15.1.1 COMPANY OVERVIEW

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPEMENTS

15.1.5 DATA BRIDGE ANALYSIS

15.2 BECTON, DICKINSON AND COMPANY

15.2.1 COMPANY OVERVIEW

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPEMENTS

15.2.5 DATA BRIDGE ANALYSIS

15.3 GERRESHEIMER, AG

15.3.1 COMPANY OVERVIEW

15.3.2 REVENUE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPEMENTS

15.3.5 DATA BRIDGE ANALYSIS

15.4 PFIZER, INC.

15.4.1 COMPANY OVERVIEW

15.4.2 REVENUE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPEMENTS

15.4.5 DATA BRIDGE ANALYSIS

15.5 SCHOTT AG

15.5.1 COMPANY OVERVIEW

15.5.2 REVENUE ANALYSIS

15.5.3 PRODUCT PORTFOLIO

15.5.4 RECENT DEVELOPEMENTS

15.5.5 DATA BRIDGE ANALYSIS

15.6 ALKERMES PLC

15.6.1 COMPANY OVERVIEW

- 15.6.2 REVENUE ANALYSIS
- 15.6.3 PRODUCT PORTFOLIO
- 15.6.4 RECENT DEVELOPEMENTS
- 15.6.5 DATA BRIDGE ANALYSIS
- 15.7 ELI LILLY AND COMPANY
 - 15.7.1 COMPANY OVERVIEW
 - 15.7.2 REVENUE ANALYSIS
 - 15.7.3 PRODUCT PORTFOLIO
 - 15.7.4 RECENT DEVELOPEMENTS
 - 15.7.5 DATA BRIDGE ANALYSIS
- 15.8 SANDOZ
 - 15.8.1 COMPANY OVERVIEW
 - 15.8.2 REVENUE ANALYSIS
 - 15.8.3 PRODUCT PORTFOLIO
 - 15.8.4 RECENT DEVELOPEMENTS
 - 15.8.5 DATA BRIDGE ANALYSIS
- 15.9 TERUMO CORPORATION
 - 15.9.1 COMPANY OVERVIEW
 - 15.9.2 REVENUE ANALYSIS
 - 15.9.3 PRODUCT PORTFOLIO
 - 15.9.4 RECENT DEVELOPEMENTS
 - 15.9.5 DATA BRIDGE ANALYSIS
- 15.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
 - 15.10.1 COMPANY OVERVIEW
 - 15.10.2 REVENUE ANALYSIS
 - 15.10.3 PRODUCT PORTFOLIO
 - 15.10.4 RECENT DEVELOPEMENTS
 - 15.10.5 DATA BRIDGE ANALYSIS

16 APPENDIX

- 16.1. RELATED REPORTS
- 16.2. CUSTOMIZABLE OPTIONS
- 16.3. SOURCE SHEET
- 16.4. BIBLIOGRAPHY

17 ABOUT DATA BRIDGE MARKET RESEARCH

I would like to order

Product name: Global Injectable Drug Delivery Market - Trends and Forecast to 2024

Product link: <https://marketpublishers.com/r/G865946B23FEN.html>

Price: US\$ 4,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G865946B23FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970